Molecular epidemiologic studies within the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Cancer Causes and Control

Volumn 12, Issue 7, 2001, Pages 627-633

  Hoque, Ashraful ^a   Albanes, Demetrius ^b   Lippman, Scott M ^a   Spitz, Margaret R ^a   Taylor, Phillip R ^b   Klein, Eric A ^c   Thompson, Ian M ^d   Goodman, Phyllis ^e   Stanford, Janet L ^f   Crowley, John J ^e   Coltman, Charles A ^g   Santella, Regina M ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g Southwest Oncology Group   (United States)

^h Mailman School of Public Health of Columbia University ^*  (United States)

Author keywords

Molecular epidemiology; Primary prevention; Prostate cancer; Selenium; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; LEPTIN; SELENIUM; SEX HORMONE; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; COLON CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DNA ADDUCT; DNA REPAIR; ENVIRONMENTAL FACTOR; GENETIC MARKER; HEREDITY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR;

COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; EPIDEMIOLOGIC STUDIES; GENETIC MARKERS; GONADAL STEROID HORMONES; HUMANS; LEPTIN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; SELENIUM; UNITED STATES; VITAMIN E;

EID: 17944379311     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011277600059     Document Type: Article

References (48)

1. SELECT: The Selenium and Vitamin E Cancer Prevention Trial, rationale and design
2. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility
3. Tissue-specific cyclic adenosine 3′, 5′-monophosphate-induced and phorol ester-repressed transcription from the human p450c17 promoter in mouse cells
4. Polycystic ovaries and male pattern baldness are associated with one allele of steroid metabolism gene CYP17
5. Promoter-specific activation of RNA polymerase II transcription by Spl
6. CYP17 and breast cancer risk: The polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1
7. Genetic control of human androgen metabolism by the CYP17 and SRD5A2 genes
8. Prostate cancer associated with CYP17 genotype
9. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
10. Glutathione S-transferase polymorphisms: Influence on susceptibility to cancer
11. Genetic metabolic polymorphisms and the risk of cancer: A review of the literature
12. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer
13. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans
14. Polymorphisms in the DNA repair gene XPD: Correlation with risk and age at onset of basal cell carcinoma
15. Polymorphisms of DNA repair gene XRCCl in squamous cell carcinoma of the head and neck
16. Human biomonitoring and the 32-postlabeling assay
17. Immunologic methods for detection of carcinogen-DNA damage in humans
18. Protein adducts in the molecular dosimetry of chemical carcinogens
19. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons
20. Arteriosclerotic plaque development is "promoted" by polynuclear aromatic hydrocarbons
21. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility
22. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo
23. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer
24. Body composition assessed by bioelectrical impedance analysis (BIA) and the correlation with plasma insulin-like growth factor (IGF-1) in normal Japanese subjects and patients with acromegaly and GH deficiency
25. Association of insulin-like growth factor-1 with body composition, weight history, and past health behaviors in the very old: The Framingham Heart Study
26. Relation between plasma insulin-like growth factor 1 (IGF-1) levels and body mass index (BM1) in adults
27. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relation of IGF binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth harmone
28. NIH Conference: Insulin-like growth factors in health and disease. IGF-1 and cancer
29. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia
30. Plasma insulin-like growth factor-1 and prostate cancer risk: A prospective study
31. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men
32. Racial differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer
33. The growth harmone: Insulin-like growth factor 1 axis is a mediator of diet restriction-induced inhibition of mononuclear cell leukemia in Fischer rats
34. Dietary restriction reduces insulin-like growth factor-1 levels, which modulates apoptosis, cell proliferation tumor progression in p53-deficient mice
35. Clinical gynecologic endocrinology and infertility
36. Serum levels of insulin-like growth factor-1 (IGF-1) and IGF-binding protein-3 in healthy centenarians: Relationship with plasma leptin and lipid concentrations, insulin action, and cognitive function
37. Insulin and insulin-like growth factor 1 antagonize the stimulation of ob gene expression by dexamethasone in cultured rat adipose tissue
38. Direct intraovarian effects of leptin: Impairment of the synergistic action of insulin-like growth factor-1 on follicule stimulating hormone-dependent estradiol 17beta production by rat ovarian granulosa cells
39. Molecular physiology of leptin and its receptor
40. Relationship between circulating leptin and peripheral fat distribution in obese subjects
41. Depot- and sex-specific differences in human leptin mRNA expression: Implications for the control of regional fat distribution
42. Acute insulin administration does not affect plasma leptin
43. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates
44. Leptin concentration in relation to overall adiposity and regional body fat distribution in Mexican Americans
45. Association between the leptin receptor gene and adiposity in middle-aged Caucasian males from the HERITAGE family study
46. Leptin in relation to prostate cancer and benign prostatic hyperplasia